Maurizio Gabrielli

Dr. Maurizio Gabrielli

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2013 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Alfonso FasanoAlfonso Fasano
Alfonso Fasano
FBFrancesco Bove
Francesco Bove
Maurizio GabrielliMaurizio Gabrielli
Maurizio Gabrielli
MMartina Petracca
Martina Petracca
MZMaria Assunta Zocco
Maria Assunta Zocco
ABAnna Rita Bentivoglio
Anna Rita Bentivoglio

1 February 2011 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Maurizio GabrielliMaurizio Gabrielli
Maurizio Gabrielli
PBPatrizia Bonazzi
Patrizia Bonazzi
Emidio ScarpelliniEmidio Scarpellini
Emidio Scarpellini
EBEmanuele Bendia
Emanuele Bendia
ELErnesto C. Lauritano
Ernesto C. Lauritano
AGAntonio Gasbarrini
Antonio Gasbarrini

1 September 2007 in Digestive Diseases
Verified
Journal Article
Closed access
PDF file
Antonio GasbarriniAntonio Gasbarrini
Antonio Gasbarrini
ELErnesto Cristiano Lauritano
Ernesto Cristiano Lauritano
Maurizio GabrielliMaurizio Gabrielli
Maurizio Gabrielli
Emidio ScarpelliniEmidio Scarpellini
Emidio Scarpellini
ALAndrea Lupascu
Andrea Lupascu
GGGiovanni Gasbarrini
Giovanni Gasbarrini
Small intestinal bacterial overgrowth (SIBO) is a clinical condition characterized by a malabsorption syndrome due to an increase in microorganisms within the small intestine. The main mechanisms restricting bacterial colonization in the upper gut are the gastric acid barrier, mucosal and systemic immunity and intestinal clearance. When these mechanisms fail, bacterial overgrowth develops. Diarrhea, steatorrhea, chronic abdominal pain, bloating and flatulence are common symptoms and are similar to those observed in irritable bowel syndrome. Breath tests (glucose and/or lactulose breath tests) have been proposed as a sensitive and simple tool for the diagnosis of bacterial overgrowth, being non-invasive and inexpensive compared to the gold standard represented by the culture of intestinal aspirates. Antibiotic therapy is the cornerstone of SIBO treatment. Current SIBO treatment is based on empirical courses of broad-spectrum antibiotics since few controlled studies concerning the choice and duration of antibiotic therapy are available at present.

1 August 2008 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
ELErnesto C. Lauritano
Ernesto C. Lauritano
Maurizio GabrielliMaurizio Gabrielli
Maurizio Gabrielli
Emidio ScarpelliniEmidio Scarpellini
Emidio Scarpellini
ALAndrea Lupascu
Andrea Lupascu
MNMarialuisa Novi
Marialuisa Novi
AGAntonio Gasbarrini
Antonio Gasbarrini

1 November 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ELErnesto Cristiano Lauritano
Ernesto Cristiano Lauritano
ABAnna Lisa Bilotta
Anna Lisa Bilotta
Maurizio GabrielliMaurizio Gabrielli
Maurizio Gabrielli
Emidio ScarpelliniEmidio Scarpellini
Emidio Scarpellini
ALAndrea Lupascu
Andrea Lupascu
AGAntonio Gasbarrini
Antonio Gasbarrini
Objectives: Small intestinal bacterial overgrowth is defined as an abnormally high bacterial population level in the small intestine. Intestinal motor dysfunction associated with hypothyroidism could predispose to bacterial overgrowth. Luminal bacteria could modulate gastrointestinal symptoms and interfere with levothyroxine absorption. The aims of the present study were to assess the prevalence and clinical pattern of bacterial overgrowth in patients with a history of overt hypothyroidism and the effects of bacterial overgrowth decontamination on thyroid hormone levels. Methods: A total of 50 consecutive patients with a history of overt hypothyroidism due to autoimmune thyroiditis was enrolled. Diagnosis of bacterial overgrowth was based on positivity to a hydrogen glucose breath test. Bacterial overgrowth positive patients were treated with 1200 mg rifaximin each day for a week. A glucose breath test, gastrointestinal symptoms, and thyroid hormone plasma levels were reassessed 1 month after treatment. Results: A total of 27 patients with a history of hypothyroidism demonstrated a positive result to the breath test (27 of 50, 54%), compared with two in the control group (two of 40, 5%). The difference was statistically significant (P < 0.001). Abdominal discomfort, flatulence, and bloating were significantly more prevalent in the bacterial overgrowth positive group. These symptoms significantly improved after antibiotic decontamination. Thyroid hormone plasma levels were not significantly affected by successful bacterial overgrowth decontamination. Conclusions: The history of overt hypothyroidism is associated with bacterial overgrowth development. Excess bacteria could influence clinical gastrointestinal manifestations. Bacterial overgrowth decontamination is associated with improved gastrointestinal symptoms. However, fermenting carbohydrate luminal bacteria do not interfere with thyroid hormone levels.

1 February 2010 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
Emidio ScarpelliniEmidio Scarpellini
Emidio Scarpellini
VVVenanzio Valenza
Venanzio Valenza
Maurizio GabrielliMaurizio Gabrielli
Maurizio Gabrielli
ELErnesto Cristiano Lauritano
Ernesto Cristiano Lauritano
GPGermano Perotti
Germano Perotti
AGAntonio Gasbarrini
Antonio Gasbarrini
Aluated by the 51Cr-ethylenediaminetetraacetic acid (51Cr-EDTA) permeability test in 52 LC patients and in 48 sex- and age-matched controls. The presence of 51Cr-EDTA was also evaluated in ascitic fluid after therapeutic paracentesis in all LC patients with ascites. RESULTS: An altered IP was found in 45% of LC patients compared with 4% of controls (P<0.00001). IP impairment was significantly associated with Child–Pugh status (75% of Child C patients vs. 39% of Child B and 22% of Child A patients), with the presence of ascites (60% in ascitic patients vs. 31% in nonascitic patients), and with a history of SBP (100% of patients with SBP vs. 50% of those without SBP). 51Cr-EDTA was present in all ascitic samples obtained from patients with SBP compared with 22% of patients without SBP. CONCLUSIONS: IP derangement was a common finding in LC, especially in patients with more advanced disease (presence of ascites and history of SBP). The presence of 51Cr-EDTA in ascites in patients with SBP suggests an altered permeability of splancnic vessels and/or peritoneal membranes. Further studies are required to assess 51Cr-EDTA urine and ascite cutoffs to set up SBP preventive strategies....